PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Tirzepatide Resolves MASH but Fibrosis Benefit Unproven in Phase 2

SYNERGY-NASH provides the first histologic evidence that dual GIP/GLP-1 receptor agonism resolves steatohepatitis in patients with moderate-to-severe fibrosis, informing where tirzepatide may fit in the emerging MASH treatment landscape.
tirzepatideGIP/GLP-1 receptor agonistMASHNASHliver fibrosissteatohepatitisphase 2 trialhepatologySYNERGY-NASHweight loss Gastroenterology / Hepatology

Background Information

Tirzepatide offers potential new hope for MASH management.

Metabolic dysfunction-associated steatohepatitis (MASH) can lead to serious liver complications and death, making effective treatments crucial. Tirzepatide significantly improved MASH resolution compared to placebo, with 62% achieving success at 15 mg versus 10% for placebo (P<0.001). This phase 2 trial suggests tirzepatide may be effective for MASH with moderate or severe fibrosis, though larger studies are needed for confirmation. Tirzepatide shows promise in treating MASH, warranting further investigation.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ, SYNERGY-NASH Investigators

Citation: Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine. 2024;391(4):299-310. doi:10.1056/NEJMoa2401943

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
⚠️ Correction Notice
This article has 1 published erratum indexed on PubMed:
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is drafted and in final pharmacist review before it publishes.